May 9th 2024
Compared with ruxolitinib, momelotinib improved mild, moderate, and severe anemia in patients with myelofibrosis who were naive to JAK inhibitors, according to the phase 3 SIMPLIFY-1 study.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Primary Myelofibrosis Outcomes Could Be Affected by Socio-Racial Factors
September 8th 2023At the SOHO 2023 Annual Meeting, Mohammad Bakri Hammami, MD, spoke about the need to address disparities related to race, sex, and age among patients with primary myelofibrosis to ensure that everyone receives high-quality treatment.
Read More
Goals of Managing Cytopenic Myelofibrosis in Younger Patients
August 29th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Naveen Pemmaraju, MD, and participants discussed the role of JAK inhibitors in managing myelofibrosis particularly in younger patients who may receive allogeneic stem cell transplant. This is the first of 2 articles based on this event.
Read More
EXCEED-ET Investigates an Alternative Option for Disease Modification in Essential Thrombocytopenia
July 16th 2023In an interview with Targeted Oncology, Lucia Masarova, MD, discussed the ongoing EXCEED-ET clinical trial and its potential to provide a new option to alter disease and ward off post-essential thrombocytopenia myelofibrosis in adult patients.
Read More
Pelabresib Leads to Hematologic Response in Hydroxyurea-Refractory or Intolerant High-Risk ET
June 9th 2023Preliminary findings from arm 4 of the phase 2 MANIFEST trial show hematologic response and symptom improvement with pelabresib in high-risk essential thrombocythemia that is refractory or intolerant to hydroxyurea.
Read More